Oxford Biomedica plc (LON:OXB)

Oxford Biomedica Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	75.28	96.88	60.65	103.72	141.29	108.94
Trading Asset Securities	-	0.02	-	-	-	0.07
Cash & Short-Term Investments	75.28	96.9	60.65	103.72	141.29	109.02
Cash Growth	39.73%	59.77%	-41.52%	-26.59%	29.60%	132.04%
Accounts Receivable	45.19	47.88	41.33	13.34	45.01	35.95
Other Receivables	13.91	17.3	13.7	7.04	12.61	6.15
Receivables	59.11	65.18	55.03	20.39	57.62	42.1
Inventory	26.51	17.33	13.57	12.87	12.63	9.52
Prepaid Expenses	7.53	6.09	3.94	4.36	3.98	3.21
Other Current Assets	-	0.15	-	-	-	-
Total Current Assets	168.43	185.65	133.19	141.33	215.5	163.84
Property, Plant & Equipment	98.82	107.63	64.3	75.69	133.78	69.73
Goodwill	-	-	-	-	0.66	-
Other Intangible Assets	24.3	25.17	29.22	30.98	105.23	0.05
Long-Term Accounts Receivable	-	-	0.03	0.04	-	-
Other Long-Term Assets	7.4	7.28	4.9	4.3	5.01	3.61
Total Assets	298.95	325.72	231.64	252.34	460.18	237.23

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	11.24	14.21	9.61	6.05	13.6	5.26
Accrued Expenses	12.25	18.97	15.04	10.27	20.63	11.9
Current Portion of Long-Term Debt	-	-	0.28	-	-	-
Current Portion of Leases	7.13	6.06	4.14	3.65	3.3	0.85
Current Income Taxes Payable	2.4	2.18	1.51	1.48	2.35	1.9
Current Unearned Revenue	43.11	42.8	24.19	22.11	19.26	13.4
Other Current Liabilities	0.04	-	3.54	0.75	-	-
Total Current Liabilities	76.17	84.22	58.32	44.32	59.66	33.31
Long-Term Debt	53.85	41.49	39.79	38.53	39.78	-
Long-Term Leases	97.67	100.58	64.55	69.27	71.21	8.49
Long-Term Unearned Revenue	5.59	0.69	1.07	5.33	1.15	1.85
Long-Term Deferred Tax Liabilities	-	-	-	-	5.59	-
Other Long-Term Liabilities	7.58	7.39	7.42	17.06	46.61	6.24
Total Liabilities	240.85	234.37	171.16	174.51	223.99	49.89

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	60.52	60.38	52.98	48.4	48.13	43.09
Additional Paid-In Capital	446.27	445.85	394.86	380.33	379.95	307.77
Retained Earnings	-457.05	-422.35	-399.5	-352.92	-198.55	-165.81
Comprehensive Income & Other	8.36	7.47	8.71	-1.81	-24.89	2.29
Total Common Equity	58.1	91.35	57.05	74.01	204.65	187.34
Minority Interest	-	-	3.44	3.83	31.54	-
Shareholders' Equity	58.1	91.35	60.49	77.83	236.19	187.34
Total Liabilities & Equity	298.95	325.72	231.64	252.34	460.18	237.23

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	158.64	148.13	108.76	111.46	114.28	9.34
Net Cash (Debt)	-83.36	-51.23	-48.11	-7.74	27	99.68
Net Cash Growth	-	-	-	-	-72.91%	200.80%
Net Cash Per Share	-0.70	-0.46	-0.47	-0.08	0.28	1.16
Filing Date Shares Outstanding	121.04	120.75	105.96	96.8	96.26	86.18
Total Common Shares Outstanding	121.04	120.75	105.96	96.8	96.26	86.18
Working Capital	92.26	101.43	74.87	97.01	155.84	130.54
Book Value Per Share	0.48	0.76	0.54	0.76	2.13	2.17
Tangible Book Value	33.79	66.18	27.83	43.03	98.77	187.29
Tangible Book Value Per Share	0.28	0.55	0.26	0.44	1.03	2.17
Machinery	93.19	86.31	70.8	65.33	61.02	40.17
Leasehold Improvements	61.68	60.61	61.29	61.06	60.23	28.15
Order Backlog	-	204	150	94	94	-

Data Source: S&P Global Market Intelligence Last updated: Sep 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 25, 2026

Data Sources Report a data error